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1. IntroductionThyroid cancer represents 3.8% of all new cases ofcancer in the United States1. In Egypt, according to theNational Cancer Institute (NCI) Registry from2002-2004 thyroid cancer represented 2.2% of femalemalignancies. The National Cancer Registry Program(NCRP) of Egypt 2008-2011 showed that thyroid canceris one of the most frequent malignancies in femalesrepresenting 3.28% while it was not one of the mostfrequent cancers in males2. The incidence is increasingall over the world3. This increased incidence over thepast three decades maybe attributed to the more use ofultrasound guided aspirations, imaging studies such ascomputed tomography, magnetic resonance imaging,and positron emission tomography scans, leading todetection of small non-palpable tumors in asymptomatic
patients4. The documented increased incidence is ofboth small non-palpable tumors5-6 and large tumors (>2cm)6. Moreover, the thyroid cancer incidence is sharplyincreasing in children, adolescents and young adults7.The current treatment modalities kept the mortality ratefor differentiated thyroid carcinoma (DTC) low despitethe recent increase in its incidence8.DTC represents the vast majority of cases and isassociated with a high 10-year survival rate (90-95%)9.Total or near-total thyroidectomy is the gold standardtherapy for DTC. Surgery is usually followed byradioactive iodine therapy (RAI) for remnant ablation oras adjuvant therapy to treat potential metastatic disease.Total thyroidectomy increases survival rates and
Purpose: Following total thyroidectomy of differentiated thyroid carcinoma (DTC),some patients are ablated with radioactive iodine I-131 (RAI). We compare thesuccess of ablation with 30 millicurie (mCi) versus 80 mCi. Methods: Werandomized the patients to 30 mCi or 80 mCi RAI after surgery. T1-T3, N0-N1, M0tumors were included (based on the AJCC 7th edition). Pre-ablation baseline serumthyroglobulin (sTg), and thyroglobulin antibody (Tg Ab) were performed. Sixmonths post-ablation successful thyroid ablation was defined as a negative wholebody scan (WBS) and undetectable sTg. Results: Out of 50 patients with DTC, 45patients fulfilled the eligibility criteria. Total thyroidectomy was performed in 27/45 (60%). 26/45 (57.8%) of patients received 30 mCi while 19/45 (42.2%)patients received 80 mCi. The median age was 37 and 36.5 years in the arms 80and 30 mCi respectively. Papillary carcinoma predominated in 42/45 (93.3%) ofpatients. T2 tumors predominated in 10/19 (52.6%), and 15/26 (57.7%) of the 80and 30 mCi arms respectively. According to the American Thyroid Association(ATA) risk classification, all of the patients had low risk disease. Success of ablationwas achieved in 15/19 (78.9%), and in 15/26 (57.7%) of the arms 80 and 30 mCirespectively. No patients developed distant metastases in both arms. The patientswho received 80 mCi had longer hospital isolation than the 30 mCi arm (p 0.008).6/26 (23.1%) patients in the 30 mCi arm were isolated for 2-4 days, whereas allthe 80 mCi arm patients were isolated for 3-5 days. Conclusion: Both 80 mCi and30 mCi RAI have similar success rate in the ablation of thyroid remnant of low riskDTC patients. The low dose is associated with fewer side effects, shorter hospitaladmission duration, and is less expensive in low risk DTC patients.
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decreases recurrence rates in patients with thyroidcancer. Molecular-targeted therapies, such as tyrosinekinase inhibitors (TKIs), have been approved in the pastfew years for the treatment of patients with advancedthyroid cancer8.Over the past several years, given the increasingincidence of low-risk DTC, there has been a growinginterest in tailoring the intensity of therapy and ofmonitoring the disease risk10-12. Lower doses of RAI areinvestigated to achieve an attractive risk-benefit ratio,namely low toxicity and no impact on quality of life. Theadvantages of lower RAI doses include lower toxicitywhich will improve quality of life, shorter hospitalisolation, and lower radiation dose to the extra-thyroidcompartments. High dose RAI ablation is associated witha higher rate of successful ablation of around 80 to87%13. However, this high dose of RAI has certaindisadvantages, including patient isolation, high cost,more incidences of adverse effects, and increased risk ofsecond malignancies14-17. A retrospective study byMazzaferri and Jhiang18 demonstrated that low-dose RAIablation (29 - 50 mCi) is as effective as high-dose RAIablation (51-200 mCi) in controlling tumor recurrenceand improving overall survival. The authors also foundno difference in the long term tumor recurrence rate(7% vs. 9%). In 1996, Bal et al.19 carried out the firstprospective randomized clinical study to evaluate theoptimal dose of radioactive I-131. They studied 149 DTCpatients with thyroid remnant after near totalthyroidectomy. The patients were randomly divided into4 treatment groups, 25-34 mCi of I-131 (27 patients),35-64 mCi (54 patients), 65-119 mCi (38 patients) and120-200 mCi (30 patients). Six months to one year afterRAI ablation the authors observed complete remnantablation in the 30 mCi group (63%), 77.8% in the 50 mCigroup, 73.7% in the 90 mCi group and 76.7% in the155mCi group. The calculated radiation-absorbed dosewas approximately 20,000 cGy delivered by 30 mCidose, about 30,000 cGy delivered by 50 mCi dose, about50,000 cGy delivered by 90 mCi, and approximately130,000 cGy by 155 mCi dose. The authors concludedthat doses above 50 mCi resulted in plateauing of thedose response curve. So, based on the dosimetry studiesthey recommended RAI doses of about 50 mCi forthyroid remnant ablation because higher doses do notappear to achieve a higher ablation rate. Severalrandomized trials and meta-analyses including bothobservational and randomized trials investigated therole of lower dose RAI for remnant ablation. Most ofthese studies showed comparable effectiveness of bothlow and high doses of postoperative ablative RAI.However, there is no recommendation for a definitedose of I-131 for remnant ablation20-25. Mäenpää et al. 25in a randomized study showed no difference betweenRAI doses of 100 mCi and 30 mCi as regards theeffectiveness of thyroid remnant ablation and long termresults.
The objective of this prospective randomized study wasto compare the success of thyroid remnant ablation withlow and high dose I-131 iodine therapy after total ornear total thyroidectomy of differentiated thyroidcarcinoma with no distant or local metastases. We alsocompared the short term adverse effects, and hospitalisolation duration.
2. Methods and MaterialsWe prospectively studied patients with the followinginclusion criteria: (1) Age 18 years or older. (2) DTC(papillary, follicular, excluding aggressive histologicsubtypes). (3) TNM stages of T1- T3 N0 N1 M0 [AJCC 7thedition]. (4) All the patients had total or near totalthyroidectomy. (5) Eastern Cooperative Oncology Group(ECOG) performance status of 0-2. Forty –five out of 50patients referred to the Clinical Oncology Department ofAin-Shams University matched the inclusion criteria.The study was conducted from June 2013 to October2015. The protocol was approved by the institutionalreview board of Faculty of Medicine, Ain-ShamsUniversity.
2.1. Preparation to Iodine remnant ablationIn preparation to ablation all the patients had thefollowing laboratory work done; serum T3, T4, TSH,baseline serum thyroglobulin, and thyroglobulinantibodies. In addition to complete blood picture, liverand kidney functions tests, serum calcium, pregnancytest for female patients in the child bearing period (CBP)and postoperative neck ultrasound. Chest x-ray was alsodone. All female patients in the CBP were referred to theGynecologic Department Ain- Shams University to usereliable contraception methods. All patients wereinstructed to have a low iodine diet for at least 2 weeksprior to iodine ablation.
2.2. Iodine- 131 remnant ablation administrationThe patients were randomized to receive either 80 mCior 30 mCi RAI. RAI remnant ablation was performedafter thyroid hormone withdrawal for 4-6 weeks untilserum TSH reached a level of 25- 30 mU/L. The patientsin the 80 mCi arm were kept in isolation till the doserate was < 5 mR/hr at 1 meter distance. Most of thepatients of the arm 30 mCi were not isolated.
2.3. Post-RAI success of ablation and follow-upA post-ablation WBS was done within 5-7 days after theadministration of I-131. Thyroxine suppression therapywas started 24-48 hours after the I-131 ablation. If anydistant uptake was detected the patient was excludedfrom the study. At 3 months post-ablation clinicalevaluation, a thyroid ultrasound (U/S), serum T3, T4 andTSH were performed. If any suspicious findings at thethyroid bed or cervical lymph nodes were detected WBSwas performed. A successful ablation was defined asnegative diagnostic WBS (5 mCi of I-131), andundetectable sTg 2 ng/mL at 6 months post ablation. If
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more than minimal activity was detected in the thyroidbed or cervical lymph nodes the I-131 would berepeated until successful ablation was achieved.
2.4. Statistical analysisAnalysis of data was done by IBM computer using SPSS(statistical program for social science version 20). TheChi-square test was used to compare qualitativevariables between groups (sex, histologic type,
successful ablation, incidence and types of and sideeffects of iodine ablation). The quantitative variables(age, duration of hospital isolation) were expressed asmean ± standard deviation and range by using theunpaired t-test. The qualitative variables wereexpressed as number and percentage. A P-value > 0.05was considered insignificant, P < 0.05 significant, and P< 0.001 highly significant.
Table 1: Clinical characteristics of patientsVariable 80 mci arm n=19 30 mci arm  n=26 P valueAgeMedianRange 3741 36.544 0.59 NSSexMaleFemale 514 521 0.45 NSHistologyPapillaryPapillary follicular variantPapillary columnar cell variantMicropapillaryFollicular
152002
212210 0.66 NSGradeOneTwoThree 1162 14111 0.30 NSTumor sizeT1T2T3 5104 10151 0.17 NSNodal involvementN0N1 181 251 0.36 NSStageIIIIII 1612 2420 0.20 NSATA riskLow risk 19 26 0.22 NSThyroglobulin (Tg) medianBaseline (after surgery)Six months 1.10.2 1.30.8 0.34 NSSurgery (Thyroidectomy)SubtotalTotalCompletion 1126 11510 0.60 NSTime from surgery to ablation (days)MedianRange 58141 61304 0.40 NSSuccess of ablation at 6 monthsSuccessfulfailure 15 (79.5%)2 (10.5%) 15 (57.7%)6 (23.1%) 0.13 NS
4 Ibrahim et al.: Radioactive iodine ablation of differentiated thyroid carcinoma International Journal of Cancer Therapy and Oncology
www.ijcto.org
© Ibrahim et al. ISSN 2330-4049
3. ResultsThe baseline characteristics of the study subjects aresummarized in Table 1. Five patients were not enrolledin the study: 1 patient had a postoperative bulkyresiduum by ultrasound and needed higher radioactiveiodine dose, 1 patient was excluded due to presence ofmetastasis diagnosed at the post-ablation WBS, 1 patienthad micropapillary carcinoma and radioactive iodineablation was not indicated, and 2 patients wereineligible after randomization.  Although we usedsimple randomization the patients’ numbers wereunequal in each group. This was because some patientswere excluded after randomization.
Figure 1: Number of Days in Hospital Isolation (P = 00.8)
3.1. PatientsThe median age was 37 years old in both arms. Femalesrepresented 35/45 (77.8%) of the patients. The majorityof patients had papillary thyroid carcinoma and itsvariants, only two patients had follicular carcinoma in
the 80 mCi arm. Stage I predominant in 16/19 patientsof arm 80 mCi and 24/26 patients of arm 30 mCi. Twopatients of the arm 80 mCi had stage III disease. T1 andT2 tumors were more frequent in the 30 mCi arm. Noneof the patients had neck dissection. All the patients hadnormal work up and none had serious comorbidities.
3.2. Pre-ablationSerum TSH values had a median value of 53 and a rangefrom 27.3 - 420 µIU/ml. The baseline sTg value wasfound to range from 0.1-248 ng/ml and had a median of1.3 depending on the mass of the residual tissue.Pre-iodine ablation serum Tg Abs was negative in 27/45,positive in 4/45, and not done in 14/45. Pre-ablationultrasound was performed in most of the patients whereit showed no residual thyroid tissue in 12/45, smallresidual in 27/45, reactionary lymph nodes in 2/45 andwas not done in 4/45 patients. The median time fromsurgery to ablation was 119 days.
3.3. Iodine remnant ablationA total of 19/45 patients were ablated with 80 mCi and26/45 patients were ablated with 30 mCi. Both arms hadno statistically significant differences in age, sex, type ofsurgery, tumor size, and pathological subtypes.
3.4. Hospital isolationThe patients of the arm 80 mCi had a longer time spentin hospital isolation that was statistically significant (P =0.008) (Table 2). All the patients who received 80 mCiwere isolated for a range of 3-5 days. The patients in thearm 30 mCi were not intended to be hospital isolated.However, only 6/26 (23%) were isolated mainlybecause of transportation issues and they spent a rangeof 2-4 days.
Table 2: Comparison between both arms as regards hospital isolation.Variables Arm 80 mCi (n=19) Arm 30 mCi (n=26) t PMean±SD 3.7 ± 1.1 2.7 ± 1.3 2.8 0.008Range 3-5 2-4
Table 3: Comparison between both arms as regards I-131 side effects.Variables Arm 80 mCi (n=19) Arm 30 mCi (n=26) t PYes 15 (78.9%) 6 (23.1%) 12.8 0.000No 4 (21.1%) 20 (76.9%)
Table 4: Comparison between both arms as regards type of side effects.Variable Arm 80 mCi (n=19) Arm 30 mCi (n=26) X2 PNeck pain 7 (36.8%) 3 (11.5%) 23 0.000Headache 7 (36.8%) 2 (7.7%)Sialadenitis 9 (47.2%) 1 (3.8%)Muscle cramps 1(5.3%) 0 (0%)No side effects 3 (15.8%) 19 (73.1%)
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Table 5: Ablation results at six months after 30 mCi and 80 mCi radioactive I-131 remnant ablation.Variable Arm 80 mCi (n=19) Arm 30 mCi (n=26)Lost follow-upOut of trial (after ablation) 2 (10.5%)0 1 (3.84%)1 (3.84%)Serum TgUndetectable (median value)Increased (due to failure of ablation)Unavailable (due to lost follow-up or out of trial afterablation)
0.2NA sTg (1/19, 5.36 %)NA sTg (2/19, 10.5 %) 0.8106.96 (3/26, 11.5 %)NA sTg (2/26, 7.7 %)
Neck US doneNormalSuspicious 17170 17107Diagnostic WBSNo uptakeThyroid bed uptakeLymph node uptakeNot done (due to lost follow up and/or out of trial)
15112
15245Successful ablation 15 15Second ablative I-131 dose 2 6Neck dissection followed by I-131 dose 1 1NA: Not Available
3.5. Adverse eventsThe proportion of patients who had adverse events washigher in the high dose arm (78.9%) versus (23.1%) inthe low dose arm that was highly statistically significant(P = 0.00) (Table 3). (Table 4) shows a comparisonbetween both arms as regards the type of side effects,where most of the patients receiving 80 mCi hadsialadenitis (9/19, 47.2%) whereas neck pain was themost frequent side effect in the 30 mCi (3/26, 11.5%).
3.6. Successful ablationAt 6 months was achieved in 15/19 patients (79.5%)who received the high-dose ablation versus 15/26(57.7%) patients ablated with low-dose. Although therewas no statistical difference (P = 0.13), these resultsindicate equal efficacy of both dose regimens.
3.7. Retreatment and recurrenceSix months post-ablation, 2 patients in the arm 80 mCi(2/19, 10.5%) had unsuccessful ablation and neededre-ablation while 2 other patients lost follow up afterreceiving the RAI dose. Both patients who requiredsecond radioiodine dose had cervical lymph nodesfailure. One patient received 100 mCi and the otherpatient had neck dissection followed by 100 mCi. On theother hand, (6/26, 23.1%) patients ablated with 30 mCirequired a second ablative dose. Two patients hadfailure at the thyroid bed, one of these patients received100 mCi and the other one received 80 mCi. Fourpatients had failure in the cervical lymph nodes one ofwhom received 80 mCi, one patient was referred to adifferent center and one was re-ablated with 30 mCi.The Last patient who had cervical lymph nodes failureunderwent neck dissection followed by 100 mCi RAItreatment.
4. DiscussionIn our clinical practice we routinely use an empiric fixeddose of 80-100 mCi I-131 for thyroid remnant ablation.Because of the possibility to use lesser activities, wedecided to conduct a prospective randomized trial withshort- term outcome assessment. We acknowledge thelow number of patients however; the strength of thepresent study is that it is a randomized single centerstudy, incorporating patients with uniform inclusion,exclusion, and ablation criteria. In our study the majorityof patients were diagnosed with early stage of thedisease, so the results are related to low risk DTCpatients treated by radical surgery.The treatment of DTC consists of surgery, radioactiveI-131 ablation, and thyroxine suppressive therapy. Therole of the RAI after thyroidectomy is known toeliminate microscopic residual disease after surgery 30,
31, 32, 33 to eliminate possible metastases, and to treatknown persistent disease10, 11, 26. The RAI remnantablation is indicated in patients with intermediate tohigh risk disease. However, RAI for low-risk disease is indebate, where most of these patients can be ablated withsurgery alone for unifocal or multifocal tumors <1 cmand without high-risk features. Low-dose iodine (30mCi) may be enough for low-risk patients to achieveablation23, 24, 27-29 with low- medium and long-termrelapse rates. The advantages of low-dose RAI includeduration of hospital isolation, decreased environmentalexposure to radioiodine, lower financial cost, and lowerrisk of secondary malignancies34. Around 15randomized controlled trials have studied low-dose RAIin low risk DTC including 2 randomized trials from Indiaconfirmed the role of low dose RAI in low risk DTC19, 22,
35. Two large prospective randomized trials, one from
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France (the ESTIMABL study) by Schlumberger et al24and the HiLo trial23 from UK by Mallick et al comparedtwo different RAI regimens for low- to intermediate riskDTC. Both studies concluded that a low activity ofradioiodine (1.1 GBq) 30 mCi is as effective as a highactivity of radioiodine (3.7 GBq) 100 mCi to ablate smallthyroid remnants after total thyroidectomy independentof the pre-treatment preparation, i.e., discontinuation ofT4 or recombinant TSH. A meta-analysis of nineprospective trials including the ESTIMABL and HiLotrials recommended using the low-dose RAI due to lesspossibility of side effects and concluded that 30 mCiI-131 is sufficient for remnant ablation36. Anothermeta-analysis included only controlled randomizedtrials in which patients with DTC were allocated to lowactivity versus a high activity RAI. The lower activity wasdefined as 1100 MBq (30 mCi) and high activity as above1100 MBq. The authors concluded that low dose RAI isas effective as high dose in patients with DTC. When theauthors performed a sensitivity analysis to include onlyhigh quality trials based on their strict criteria, theydetected no difference in successful ablation ratebetween low and high activity37.In the present study all the patients had low-risk earlystage DTC; they were randomized to receive 30 mCi or80 mCi RAI. Total or subtotal thyroidectomy was theleast accepted surgery to be included in the trial. In thistrial we showed that low dose RAI (30mCi) was aseffective as high dose RAI (80 mCi) for thyroid remnantablation in early stage low risk DTC. Six monthspost-ablation WBS was negative in 15/19 (79.5%) of thehigh dose arm and 15/26 (57.7%) of the low dose armpatients. The median serum undetectable level of sTgpost-ablation was 0.2 ng/ml in the 80 mCi arm (in 84.2%of patients) versus 0.8 ng/ml (80.8% of patients) in the30 mCi arm (P = 0.22). The ablation rate in our cohortwas similar to a randomized prospective study of 40patients by Zaman et al.38 at 6 months post-ablation anegative WBS was detected in 70% of patients treatedwith 100 mCi of I-131 (Group A) and 50% of patientstreated with 50 mCi of I-131 (Group B). Ha et al 39 foundthat the first RAI of 29.73 mCi was enough to achieveremnant ablation in 68.8% of patients with low tointermediate risk thyroid cancer as assessed by serumTg and post-ablation diagnostic WBS. The ablationsuccess rate of the present study was lower than that ofsome randomized trials, ranging from 90-94% 23, 24which could be due to the different criteria for completeablation. Bal et al.40 retrospectively studied patientswith low risk thyroid carcinoma, divided the patientsinto two groups, group 1(Group-1) patients weresurgically ablated and received no RAI, group 2(Group-2) patients had significant remnant in thyroidbed and received 30 mCi I-131. Among the (Group-2)126 (82.3%) patients achieved successful ablation at theinitial 6–9 months follow-up, whereas 27 (17.7%)patients failed to achieve ablation of thyroid remnant.
Short-term adverse events associated with high doseI-131 ablation of DTC are fairly common41, 42. Earlycomplications include gastrointestinal symptoms,radiation thyroiditis, sialadenitis/xerostomia, bonemarrow suppression, gonadal damage, dry eye, andnasolacrimal duct obstruction. Most of our patients inthe 80 mCi group had side effects 84.2% whereas only26.9% of patients receiving 30 mCi had adverse effects.In the randomized study by Mallick et al.23-the HiLotrial- the adverse event rate was 21% among patientsreceiving 30 mCi (220 patients) versus 33% amongpatients receiving 100 mCi (218 patients) (P = 00.7).Similarly in our cohort the incidence of short term sideeffects favored the high dose arm (P = 0.000). Forexample rates of neck pain in this present study was(11.5% versus 36.8% in the 30 and 80 mCi armsrespectively, while in the HiLo trial neck pain occurredat rates of 7% and 17% in the 30 and 100 mCi groupsrespectively. Van Nostrand et al15 reported that about20% of patients presented with neck pain or swelling. Lu
et al.43 treated 117 patients with DTC afterthyroidectomy with RAI 131 at doses ranging from100-250 mCi for remnant ablation or treating distantmetastases. Among 117 patients, 55 cases complained ofneck pain, salivary gland pain or swelling occurred in 15patients, headache in 10 patients, and fatigue or generalmalaise in 6 patients. In the present study among 45patients 9 patients developed headache (7 cases in the80 mCi arm, 2 cases in the 30 mCi arm), fatigue (4patients received 80 mCi, 2 patients received 30 mCi),and sialadenitis (9 patients ablated with 80 mCi, and 1patient ablated with 30 mCi). Administering 30 mCireduces the adverse events to the patients and reducesthe radiation exposure to household contacts of patientsto well below the maximum annual limit of 5.0 mSv 44.In the HiLo trial23, a total of 21/220 patients (9.5%) whoreceived low dose RAI needed a subsequent seconddose, in comparison to 9/218 patients (4.15%) of thehigh dose group (P = 0.02). Among the 21 patients in thelow-dose group, the second RAI doses were 29.7 mCiI-131 in 1 patient, 80 mCi-108 mCi in 8 patients, andmore than 108 mCi in 21 patients. While all the 9patients in the high dose group received more than 108mCi. The RAI dose retreatment was given because ofconcerns about an initially positive scan or rise in thethyroglobulin levels at 6-9 months in patients receivinglow dose radioiodine45, 46. In the present study, amongthe 30 mCi arm 6/26 patients (23.1%) requiredretreatment with RAI versus 2/19 (10.5%) patients inthe 80mCi arm (P = 0.37). The second RAI doses in thearm 30 mCi were 100mCi in 1 patient with thyroid bedfailure, 80 mCi in 2 patients (one thyroid bed failure, onecervical lymph node failure), 30 mCi in 2 patients (bothwith cervical lymph node failure) and neck dissectionfollowed by 120 mCi in 1 patient. As for the 80 mCi armthe second doses were 80 mCi in 1 patient with cervicallymph node failure and 100 mCi in a patient withthyroid bed failure. Cho et al.47 reported a successful
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confirmed remnant ablation in 51% of patients whoreceived 29.7 mCi, which was achieved in only 24% ofpatients at the first RAI ablation. Kukulska et al.48conducted a two-stage prospective randomized study of309 patients who underwent total or near totalthyroidectomy. The first stage compared 30 mCi(86/309 patients) versus 60 mCi (128/309 patients)and the second stage compared 60 mCi versus 100 mCi(95/309 patients). In the group treated by 30 mCi 22%of patients needed second ablative dose of I-131. Thusthe cumulative RAI activity administered was greaterthan 100 mCi in 22% of patients. Similarly 13.3%(128/309 patients) and 11.2% (95/309 patients) ofpatients treated with 60 and 100 mCi respectivelyrequired second ablative doses.The patients who receive high dose ablative RAI requirehospital isolation. Some of these patients complainabout the inconvenience of isolation and the anxietyfrom the solitude. In the HiLo trial23 patients whoreceived low dose RAI had shorter hospital isolationduration than those who received high dose RAI, where39.6% versus 7.1% required only 1 day in hospitalisolation and 13% versus 36.3% required 3 days ormore (P < 0.001 for both comparisons). A meta-analysisby Cheng et al.36 showed that patients receiving lowdose I-131 spent less time in hospital isolation thanpatients receiving high dose I-131 (P <.05) withoutsignificant heterogeneity between studies (P = 0.43).These data accord with the results of our study wherepatients ablated with 80 mCi had a significantly longerhospital isolation (3-5 days) compared to the patientsablated with 30 mCi (2-4 days) (P = 0.008). Only 5/26(19.2%) patients in the low dose arm were hospitalisolated due to various non-medical reasons such aspregnant wife, or patients coming from distantgovernorates.The number of studies evaluating differences in longterm outcomes in patients treated with high or lowI-131 is limited. Bal and Padhy49 in their review ofradioiodine remnant ablation could not confirm asignificant, consistent, benefit of RAI in decreasingcause-specific mortality or recurrence in low-risk DTC. Arandomized clinical trial is needed to study thelong-term effect of RAI in low-risk thyroid carcinomas.Kukulska et al.48 designed a two- stage randomizedclinical trial where 309 patients with low-risk DTC aftertotal or near total thyroidectomy were ablated with 30mCi versus 60 mCi in the first stage then they compared60 mCi versus 100 mCi in the second stage. The authorsevaluated the 5 years efficacy of thyroid remnantablation and found no significant difference using 30, 60,and 100 mCi. The local relapse was stated in 2 (2.4%), 4(3%) and 3 (3%) patients treated with I-131 activities of30 mCi, 60 mCi and 100 mCi respectively. The patientswere evaluated with stimulated serum Tg and I-131scan or by radiological examinations. Bal et al.40 studiedretrospectively the long term outcome (recurrence,
persistence and progression of disease) of RAI thyroidremnant ablation in low risk DTC. The authors classifiedthe patients into two groups Group-1: 169 patients whowere surgically ablated and Group-2: 153 patients whowere ablated with 30 mCi RAI due to presence ofsignificant remnant in thyroid bed. Following a medianfollow-up duration of 10.3 years, one patient in Group-1(n = 169) developed nodal recurrence at 14 months forwhich the patient received single dose 50 mCi RAI. Asregards Group-2 126/153 of patients were ablated withsingle dose of RAI, one of these patients had recurrence.While the remaining 27/153 (29.7%) patients inGroup-2 eight patients had persistent disease aftermultiple RAI doses. The event-free survival rates were99.4% and 94.1% (P = 0.006) in Group-1 and Group-2,respectively. Mazzaferri and Kloos30 found no differencein 30-yr recurrence rates (4 and 6%, respectively; P =0.1) between low-activity (29–50 mCi) and high-activity(51–200 mCi) I-131 remnant ablation groups.
5. ConclusionWe demonstrated that both 80 mCi and 30 mCi ofradioactive Iodine (I-131) have similar success rates inthe ablation of thyroid remnant of low risk differentiatedthyroid cancer patients. The 30 mCi I-131 dose has theadvantage of fewer side effects, shorter hospitaladmission duration, and lower expenses in low risk DTCpatients. This is in agreement with differentmeta-analyses of retrospective studies and the smallnumber of randomized studies in the literature.However, these findings need to be confirmed with along- term well designed trial to study the adverseeffects, the incidence of relapse and metastases of highversus low dose radioactive iodine ablation in low riskDTC. RAI ablation omission may be considered in somelow risk DTC patients who can be only surgicallyablated. Two ongoing randomized clinical trials compareRAI (30 mCi) versus no RAI in low risk DTC patients.
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